Exclusive Summary

• First-in-class & Precision Targeting: UB687 is an AI-designed lytic enzyme (Lysin) specifically targeting Gardnerella, the main pathogen of Bacterial Vaginosis (BV), currently in Phase I.
• Overcomes Resistance & Recurrence: Highly effective against metronidazole-resistant strains (up to 90% resistance rate), penetrates biofilms to eliminate pathogen reservoirs, and shows zero resistance induction over continuous passaging.
• Microbiome-Sparing Efficacy: Selectively kills Gardnerella and provides rapid symptom relief expected within 12 hours, while perfectly preserving protective lactobacilli flora.
• Excellent Safety Profile: Designed for localized vaginal administration, ensuring no systemic exposure and a high safety margin.
• High Out-Licensing Appeal: Positioned to replace failing broad-spectrum antibiotics, offering a premium asset for global pharmaceutical companies looking to expand their Women's Health or anti-infective portfolios with a highly differentiated, non-traditional therapy.

Asset Materials

Contact Us for Full Materials